Get the Stockscreener App
4.05
8.16%
-0.36
After Hours:
4.05
X 4 Pharmaceuticals Inc stock is traded at $4.05, with a volume of 642.33K.
It is down -8.16% in the last 24 hours and up +1.25% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.41
Open:
$4.42
24h Volume:
642.33K
Relative Volume:
1.07
Market Cap:
$381.99M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.8924
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
+0.50%
1M Performance:
+1.25%
6M Performance:
+4.65%
1Y Performance:
+183.22%
1-Day Range:
$4.015
$4.48
1-Week Range:
$3.84
$4.48
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.05 | 415.95M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
480.25 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
663.09 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
876.25 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.95 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
288.06 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Form 4 Shuttle Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
Form 4 Adial Pharmaceuticals Inc For: 13 July By Investing.com - Investing.com Canada
XFOR Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentAdjusted Earnings Analysis - dars.gov.et
X4 Pharmaceuticals (XFOR) Q1 2026 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Proxy filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Q4 2025 earnings summary - Quartr
X4 Pharmaceuticals (XFOR) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
X4 Pharmaceuticals (XFOR) Corporate presentation Summary - Quartr
X4 Pharmaceuticals (XFOR) Registration filing Summary - Quartr
X4 Pharmaceuticals (XFOR) Rallies 11.36% as Positive Sentiment Drives Price Above Key SupportProfit Surge Picks - Bölüm Sonu Canavarı
Form 4 Rigel Pharmaceuticals Inc For: 10 July By Investing.com - Investing.com Nigeria
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Shuttle Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ironwood Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals stock focuses on rare disease pipeline after Nasdaq listing - ad-hoc-news.de
Form 4 Mirum Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com Nigeria
Form 4 Oric Pharmaceuticals Inc For: 8 July By Investing.com - Investing.com South Africa
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead - TradingView
X4 Pharmaceuticals (XFOR) Stifel 2024 Healthcare Conference Summary - Quartr
Form 4 Eton Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Crinetics Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Form 4 Regeneron Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Form 4 Vertex Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Canada
Form 4 ANI Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Nigeria
Price to earnings forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR - TradingView
Enterprise value to revenue forward of X4 Pharmaceuticals, Inc. – LS:A3E4QR - TradingView
XFOR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Price to sales forward of X4 Pharmaceuticals, Inc. – NASDAQ:XFOR - TradingView
Form 4 Shuttle Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals CFO David Kirske sells $36,428 in common stock By Investing.com - Investing.com Canada
Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax - Stock Titan
Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085 - Stock Titan
X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership - Stock Titan
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
X4 Pharmaceuticals Announces Appointment of Kelly Gold as an Independent Director and Member of the Audit Committee, Effective July 1, 2026 - marketscreener.com
Form 4 Adial Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - The Manila Times
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com Canada
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors - The Manila Times
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Nigeria
Form 4 Vertex Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
5.60%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):